NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT06704724 2026-03-13A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.PfizerPhase 1 Active not recruiting30 enrolled
NCT05009069 2026-01-22A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal CancerHoffmann-La RochePhase 2 Active not recruiting58 enrolled
NCT05983133 2026-01-22A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid TumorsSeagen Inc.Phase 1 Active not recruiting65 enrolled
NCT05544929 2026-01-06A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersNovartisPhase 1 Active not recruiting126 enrolled
NCT04607421 2025-08-14A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal CancerPfizerPhase 3 Active not recruiting831 enrolled 2 FDA
NCT02403505 2025-06-17CEA+RC-BCGMedicine Invention Design, IncPhase 1 Active not recruiting20 enrolled
NCT05179824 2025-05-06Tempus Priority Study: A Pan-tumor Observational StudyTempus AIActive not recruiting1,000 enrolled
NCT05462717 2024-11-07Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsRevolution Medicines, Inc.Phase 1 Active not recruiting222 enrolled